Guided Therapeutics Inc. (OTCMKTS:GTHP) Short Interest Update

Guided Therapeutics Inc. (OTCMKTS:GTHP) saw a significant drop in short interest in July. As of July 15th, there was short interest totaling 1,437 shares, a drop of 92.7% from the June 30th total of 19,653 shares. Based on an average daily volume of 29,293 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Guided Therapeutics Trading Down 2.7%

Shares of OTCMKTS:GTHP traded down $0.01 during mid-day trading on Friday, hitting $0.25. 5,100 shares of the company traded hands, compared to its average volume of 8,281. The stock has a 50-day moving average price of $0.24 and a two-hundred day moving average price of $0.28. Guided Therapeutics has a 12-month low of $0.12 and a 12-month high of $0.54. The stock has a market cap of $24.43 million, a P/E ratio of -6.33 and a beta of 0.72.

Guided Therapeutics (OTCMKTS:GTHP) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.01) EPS for the quarter.

About Guided Therapeutics

Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S.